Vaccine Mess Alert

What Kind of Doctor Do I Need? Slideshow
Medical Authors and Editors: Frederick Hecht, MD and Barbara K. Hecht, PhD

Oct 6, 2004 -- The sudden shortfall in flu vaccine has prompted the US Department of Health and Human Services to issue a press release. In it HHS admits that the situation presents "a serious challenge to our vaccine supply for the upcoming flu season."

We present the HHS press release (below) and our view of the situation.

A "Serious Challenge"

To say that the situation presents a "serious challenge" may be something of an understatement. Coming just as the flu season is starting, the loss of the Chiron flu vaccine means there will almost surely be a very significant shortage of flu vaccine this winter.

Tommy Thompson, secretary of HHS echoed the challenge theme at his news conference yesterday, saying: "This is very disappointing news that creates a serious challenge to our vaccine supply for the upcoming season."

What Happened

The Medicines and Healthcare Products Regulatory Agency in Britain has suspended Chiron's manufacturing license for making flu vaccine for three months because of a concern about sterility. What that means is that they found contamination.

In fact, back in August, contamination was found. It involved a type of bacteria called Serratia. This type of bacteria is commonly found in the environment. It occurs on plants, in soil, and in water.

Serratia

Serratia is normally not harmful to healthy people but it is what is known as an opportunistic pathogen. Given the opportunity, Serratia can spell trouble.

In people with a compromised (weakened) immune system, Serratia can cause infection of the blood (sepsis), wound infections, and infections of the endocardium (of the heart) and the urinary and respiratory tracts.

And part of the problem is that the high-risk groups for the flu who most need the flu vaccine are precisely those with a weakened immune system.

Another part of the problem is that the finding of Serratia in the vaccine is a red flag, It is a warning that who knows what else may be contaminating the vaccine.

A Coalition Problem

This is tru

ly an Anglo-American coalition problem. The factory is in Liverpool (from whence came the Beetles). But the plant belongs to Chiron Corporation, an American biotech company based in Emeryville, California (in the San Francisco Bay area). Chiron acquired the British owner of the Liverpool plant, PowderJect Pharmaceuticals, last year and has reportedly invested heavily to increase the supply of the vaccine, called Fluvirin, to the US. About 90% of the vaccine produced by the plant was destined for the US.

Caught Off Guard

The suspension of Chiron's Liverpool license appears to have caught the US government by surprise. "We had no idea," Mr. Thompson said yesterday. "In fact we didn't get notified until this morning.''

Some Questions

Why was the US government caught off guard? The contamination with Serratia has been known since August. It is now October.

Was the US Food & Drug Administration remiss? The FDA licensed the Liverpool plant to supply the US. Is the FDA not responsible for overseeing the production of the vaccine there?

The Medicines and Healthcare Products Regulatory Agency in Britain did their job but did the FDA? Why were they not on the same page?

The Sum of the Matter

The new shortfall in flu vaccine is really nothing new. It is only the latest of many signs that the US supply of vaccines is in perilous shape. "The vaccine infrastructure is frail," said Dr. Paul Offit, chief of infectious diseases at CHOP (Children's Hospital of Philadelphia), according to the New York Times.

Since 1998, there have been shortages of 9 of the 12 vaccines for American children. Little wonder. Seven of the 12 vaccines for kids are made by a one company. And only a few companies make the majority of all vaccines for the US.

What is needed is for the US government to not just put a bandaid on the flu vaccine problem but to address the whole vaccine mess. Free market forces have failed to provide a reliable supply of vaccines. The government has got to do more than issue press releases.


Statement from the Department of Health and Human Services Regarding Chiron Flu Vaccine

Clearly, the loss of the Chiron flu vaccine poses a serious challenge to our vaccine supply for the upcoming flu season. Chiron was to produce between 46-48 million doses of influenza vaccine for the United States. The Department has begun pursuing contingencies for this loss of supply.

We currently anticipate having approximately 54 milli

on doses of influenza vaccine from Aventis and about another 1-2 million doses of FluMist nasal spray. HHS had planned for a vaccine supply of about 100 million doses this season, after a demand of about 87 million doses last flu season.

Our immediate focus will be on making sure that the supply we do have reaches those who are most vulnerable. The Centers for Disease Control and Prevention is convening its Advisory Committee on Immunization Practices to prioritize its recommendations on who should get the flu vaccine for this season based on the new vaccine supply information.

We will need the help of the public, the public health community and the medical community to make sure that the vaccine goes to those who truly need it most.

We are in the process of learning more detailed information about why the UK regulatory authority suspended Chiron's license for three months and whether anything can be done to address the issues involved. The Department of Health and Human Services, including its Food and Drug Administration, Centers for Disease Control and Prevention, and National Institutes of Health, are working with their counterparts in the British government as well as Chiron regarding this matter.

The Department also has begun exploring whether more flu vaccine can be manufactured for this flu season. This includes working with Aventis on its ability to provide more vaccine. At this point, however, it is not known whether it's possible to get more vaccine.

HHS and its agencies will make more information available regarding the influenza vaccine supply as it becomes available.

Source: US Department of Health and Human Services (HHS) news release Oct 5,2004


Related Links

  • Flu Vaccine Shortage Alert (Statement from the CDC)
  • influenza nasal vaccine, FluMist (drug information)
  • Flu Vaccination (article)
  • Influenza (Flu) (article)
  • Cold, Flu, Allergy (article)
  • Cold and Flu Center

Subscribe to MedicineNet's General Health Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Reviewed on 10/6/2004

Health Solutions From Our Sponsors